Bayer acquires Noria, PSMA Therapeutics
Deal expands prostate cancer pipeline
June 4, 2021
9:31 am
Bayer said June 3 it agreed to acquire Noria Therapeutics Inc. (Noria) and PSMA Therapeutics Inc., through which the Whippany-based company will broaden its existing oncology portfolio of targeted alpha therapies.
The deal, for which financial details were not disclosed, will see Bayer pick up exclusive rights to two investigational therapies for prostate cancer that will complement the already approved therapy Xofigo, according to a release from the company.
Targeted alpha therapies, or TATs, treat difficult tumors by delivering alpha radiation inside the body using either a bone-seeking property or through the combination of alpha radionuclides with specific molecules.